<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/72607">
      <dc:title>Determination of Exosome Mitochondrial DNA as a Biomarker of Renal Cancer Aggressiveness</dc:title>
      <dc:creator>Arance, Elena</dc:creator>
      <dc:creator>Ramírez, Viviana</dc:creator>
      <dc:creator>Rubio Roldán, Alejandro</dc:creator>
      <dc:creator>Ocaña Peinado, Francisco</dc:creator>
      <dc:creator>Romero Cachinero, Catalina</dc:creator>
      <dc:creator>Jódar Reyes, Ana Belén</dc:creator>
      <dc:creator>Vázquez Alonso, Fernando</dc:creator>
      <dc:creator>Martínez González, Luis Javier</dc:creator>
      <dc:creator>Álvarez Cubero, María Jesús</dc:creator>
      <dc:subject>Biomarker</dc:subject>
      <dc:subject>Extracellular vesicles</dc:subject>
      <dc:subject>Exosome</dc:subject>
      <dc:subject>Mitochondrial DNA</dc:subject>
      <dc:subject>Renal cancer</dc:subject>
      <dc:description>This study is partially supported by ID#53169721 project funded by Pfizer and the exosomes characterization was financed thanks to the grant PY20_00241 (FEDER/Junta de Andalucia-Regional Ministry of Economic Transformation, Industry, Knowledge and Universities).</dc:description>
      <dc:description>Here, the role of non-invasive biomarkers in liquid biopsy was evaluated, mainly in exosomes and mitochondrial DNA (mtDNA) as promising, novel, and stable biomarkers for renal cell carcinoma (RCC). A total of 140 fractions (named from B to F) obtained by ultracentrifugations of whole blood samples from 28 individuals (13 patients and 15 controls) were included. Nanoparticle Tracking Analysis (NTA) was conducted to characterized exosomal fraction. Subsequently, an analysis of digital PCR (dPCR) using the QuantStudio (TM) 3D Digital PCR platform was performed and the quantification of mtDNA copy number by QuantStudioTM 12K Flex Real-Time PCR System (qPCR) was developed. Moreover, Next Generation Sequencing (NGS) analyses were included using MiSeq system (Illumina, San Diego, CA, USA). An F fraction, which contains all exosome data and all mitochondrial markers, was identified in dPCR and qPCR with statistically significant power (adjusted p values &lt;= 0.03) when comparing cases and controls. Moreover, present analysis in mtDNA showed a relevant significance in RCC aggressiveness. To sum up, this is the first time a relation between exosomal mtDNA markers and clinical management of RCC is analyzed. We suggest a promising strategy for future liquid biopsy RCC analysis, although more analysis should be performed prior to application in routine clinical practice.</dc:description>
      <dc:date>2022-02-02T09:29:38Z</dc:date>
      <dc:date>2022-02-02T09:29:38Z</dc:date>
      <dc:date>2021-12-31</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Arance, E... [et al.]. Determination of Exosome Mitochondrial DNA as a Biomarker of Renal Cancer Aggressiveness. Cancers 2022, 14, 199. [https://doi.org/10.3390/cancers14010199]</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/72607</dc:identifier>
      <dc:identifier>10.3390/cancers14010199</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>